Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective

Value in Health

Volumn 8, Issue 6, 2005, Pages 618-628

  Benner, Joshua S ^a,d   Smith, Timothy W ^a   Klingman, David ^a   Tierce, Jonothan C ^a   Mullins, C Daniel ^b   Pethick, Ned ^c   O'Donnell, John C ^c  

^a ValueMedics Research   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c ASTRAZENECA   (United Kingdom)

^d ValueMedics Research LLC   (United States)

Author keywords

Cost effectiveness; Hydroxymethylglutaryl CoA reductase inhibitors; Hypercholesterolemia; Managed care

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MONTE CARLO METHOD; PRIORITY JOURNAL; REIMBURSEMENT; RHABDOMYOLYSIS; STROKE; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 30944441067     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2005.00055.x     Document Type: Article

References (44)

1. American Heart Association. 2004 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association, 2003.
2. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
3. Shepherd J, Cobbe SM, Ford I, et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
4. Sacks FM, Pfeffer MA, Moye LA, et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
5. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
6. Downs JR, Clearfield M, Weis S, et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
7. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvistatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
8. Serruys PWJC, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. JAMA 2002;287:3215-22.
9. Jackevicius CA, Anderson GM, Leiter L, Tu JV. Use of the statins in patients after acute myocardial infarction: does evidence change practice? Arch Intern Med 2001;161:183-8.
10. Lemaitre RN, Furberg CD, Newman AB, et al. Time trends in the use of cholesterol-lowering agents in older adults. Arch Intern Med 1998;158:1761-8.
11. Hoerger TJ, Bala MV, Bray JW, et al. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998;82:61-5.
12. Stafford RS, Blumenthal D, Pasternak RC. Variations in cholesterol management practices of U.S. physicians. J Am Coll Cardiol 1997;29:139-46.
13. Fonarow GC, French WJ, Parsons LS, et al. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation 2001;103:38-44.
14. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
15. Foley KA, Simpson RJ, Crouse JR, et al. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003;92:79-81.
16. Ford ES, Mokdad AH, Giles WH, Mensah GA. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2003;107:2185-9.
17. McKenney JM, Jones PH, Adamczyk MA, et al. Comparison of the efficacy of rosuvastatin vs. atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003;19:689-98.
18. Academy of Managed Care Pharmacy. Format for Formulary Submissions, Version 2.0. Alexandria, VA: Academy of Managed Care Pharmacy, 2002.
19. Garber AM, Weinstein MC, Torrance GW, Kamlet MS. Theoretical foundations of cost-effectiveness analysis. In: Gold MR, Siegel JE, Russel LB, Weinstein MC, eds., Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
20. Siegel JE, Weinstein MC, Torrance GW. Reporting cost-effectiveness studies and results. In: Gold MR, Siegel JE, Russel LB, Weinstein MC, eds., Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
21. Olsson AG, Istad H, Luurila O, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002;144:1044-51.
22. Brown WV, Bays HE, Hassman DR, et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002;144:1036-43.
23. AstraZeneca LP. Crestor® (rosuvastatin calcium) prescribing information. August 2003.
24. First Data Bank. Data on file, AstraZeneca.
25. Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin vs. lovastatin in primary hypercholesterolemia. Am J Cardiol 1997;79:1475-81.
26. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs [Editorial]. Am J Cardiol 1997;80:106-7.
27. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001;111:185-91.
28. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Cholesterol Education Program, National Heart Lung and Blood Institute November 19, 2002. WWW document: Available from: http://www.nhlbi.nih.gov/guidelines/ cholesterol/ atp3_rpt.htm [Accessed June 4, 2004].
29. 2004 National Physician Fee Schedule Relative Value File. WWW document: Available from: http://www.cms.hhs.gov/providers/pufdownload/ rvudown.asp [Accessed June 4, 2004].
30. 2004 Clinical Diagnostic Laboratory Fee Schedule. WWW document: Available from: http://www. cms.hhs.gov/providers/pufdownload/clfdown.asp [Accessed June 4, 2004].
31. Ganz DA, Kuntz KA, Jacobson GA, Avorn J. Cost-effectiveness of 3-hydroxy-3-methylglutaryl Coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med 2000;132:780-7.
32. First DataBank National Drug Data File. Data on file, Astra Zeneca.
33. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90.
34. Olsson GO. Safety and efficacy of rosuvastatin [Letter]. Lancet 2004;364:135.
35. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
36. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985;5:157-77.
37. Briggs AH, O'Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 2002;23:377-401.
38. Zetia® (ezetimibe) Prescribing Information. March 2003, Merck/Schering-Plough Pharmaceuticals, Inc., Table 2.
39. Fitterman LK, Williams SA. A descriptive review of statin utilization patterns. Am Heart J 2002;144:905-6.
40. Frolkis JP, Pearce GL, Nambi V, et al. Statins do not meet expectation for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002;113:625-9.
41. Morrison A, Glassberg H. Determinants of the cost-effectiveness of statins. J Manag Care Pharm 2003;9:544-51.
42. Ohsfeldt RL. Challenges in evaluating the cost-effectiveness of statins [Letter]. J Manag Care Pharm 2004;10:81-2.
43. Hay JW. Evaluating the cost-effectiveness of statins [Letter]. J Manag Care Pharm 2004;10:79-81.
44. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;93:152-60.